ProCE Banner Activity

CheckMate-744: Nivolumab Plus Brentuximab Vedotin in Younger Patients With R/R Classical Hodgkin Lymphoma

Slideset Download
Conference Coverage
Standard-risk younger patients with R/R cHL achieved high CMR with nivolumab plus brentuximab vedotin as first-line salvage therapy.

Released: June 03, 2020

Expiration: June 02, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono